Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Blood (2024) 144 (7): 714–728.

https://doi.org/10.1182/blood.2024024310

Published: 2024

Includes: Supplemental data

Journal Articles

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Blood (2024) 143 (19): 1931–1936.

https://doi.org/10.1182/blood.2023023096

Published: 2024

Includes: Supplemental data

Journal Articles

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Sylvie D Freeman, Amanda Gilkes, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panos Kottaridis, Claire Arnold, Ulrik Malthe Overgaard, Mike Dennis, Charlotte Wilhelm-Benartzi, Richard Dillon, Nigel Russell

Blood (2023) 142 (Supplement 1): 425.

https://doi.org/10.1182/blood-2023-179033

Published: 2023

Journal Articles

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Blood (2023) 142 (Supplement 1): 2939.

https://doi.org/10.1182/blood-2023-179036

Published: 2023

Journal Articles

Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial

Jad Othman, Richard Dillon, Charlotte Wilhelm-Benartzi, Steve Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, William Villiers, Michelle Kleeman, Amanda Gilkes, Nicola Potter, Ulrik Malthe Overgaard, Priyanka Mehta, Panos Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Mike Dennis, Nigel H. Russell

Blood (2022) 140 (Supplement 1): 1036–1038.

https://doi.org/10.1182/blood-2022-159433

Published: 2022

Journal Articles

FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

Nigel H. Russell, Charlotte Wilhelm-Benartzi, Steve Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, Ulrik Malthe Overgaard, Amanda Gilkes, Jad Othman, Nicola Potter, Richard Dillon, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Sylvie D Freeman, Mike Dennis

Blood (2022) 140 (Supplement 1): 526–528.

https://doi.org/10.1182/blood-2022-162377

Published: 2022

NARROW

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial

FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

Email alerts

ASH Publications

American Society of Hematology

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial

FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only